Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 2

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
1.05) 
    $(0.50) 
    $(1.49) 
    $(1.11)

    Weighted average common shares outstanding – basic and diluted 
     23,298,455  
     19,307,323  
     22,899,539  
     18,666,898 

    COMPREHENSIVE LOSS 

    Net loss 
    $(24,458) 
    $(9,746) 
    $(34,197) 
    $(20,771)
  
    Other comprehensive income (loss) – foreign currency translation 
     (153) 
     (44) 
     (188) 
     86 
  
    Total comprehensive loss 
    $(24,611) 
    $(9,790) 
    $(34,385) 
    $(20,685)

The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.

2

INMUNE BIO INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES
IN STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED JUNE 30,
2025

(In thousands, except share amounts)

(Unaudited)

    Accumulated  

    Additional  
    Other  
       
    Total 

    Common Stock  
    Paid-In  
    Comprehensive  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Capital  
    Loss  
    Deficit  
    Equity 
  
    Balance as of December 31, 2024 
     22,280,451  
    $22  
    $195,754  
    $(575) 
    $(163,104) 
    $32,097 
  
    Stock-based compensation 
     -  
     -  
     2,076  
     -  
     -  
     2,076 
  
    Sale of common stock for cash 
     649,860  
     1  
     5,272  
     -  
     -  
     5,273 
  
    Exercise of warrants for cash 
     100  
     -  
     1  
     -  
     -  
     1 
  
    Loss on foreign currency translation 
     -